s6y

SAB Biotherapeutics, Inc.

Ticker
SABS
CIK
1833214
Industry
Biological Products, (No Diagnostic Substances)
Formerly
Big Cypress Acquisition Corp.

Financials 32

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024
  9. 10-Q Quarterly Report for period ending Sep 30, 2024
  10. 10-Q Quarterly Report for period ending Jun 30, 2024

All 32 financials filings

News 82

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 82 news filings

Ownership 167

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 4 Statement of changes in beneficial ownership of securities
  10. 4 Statement of changes in beneficial ownership of securities

All 167 ownership filings

Prospectus 62

  1. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  4. 424B5 Prospectus filed pursuant to Rule 424(b)(5)
  5. S-3 Registration statement for specified transactions by certain issuers
  6. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  7. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  8. S-3/A Registration statement for specified transactions by certain issuers
  9. S-3 Registration statement for specified transactions by certain issuers
  10. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

All 62 prospectus filings

Proxies 12

  1. DEF 14A Definitive proxy statements
  2. DEF 14A Definitive proxy statements
  3. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  4. DEF 14A Definitive proxy statements
  5. DEF 14A Definitive proxy statements
  6. DEF 14A Definitive proxy statements
  7. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition
  8. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  9. DEF 14A Definitive proxy statements
  10. PRE 14A Preliminary proxy statement not related to a contested matter or merger/acquisition

All 12 proxies filings

Other 81

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G/A
  4. 25-NSE Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
  5. SCHEDULE 13G/A
  6. SCHEDULE 13G/A
  7. SCHEDULE 13G/A
  8. SCHEDULE 13G/A
  9. SCHEDULE 13G/A
  10. SCHEDULE 13G/A

All 81 other filings